Latin America Immunohistochemistry Market

Latin America Immunohistochemistry Market Size (2022 to 2027)

As per our report, the size of the Latin America Immunohistochemistry Market has been estimated at USD 150.08 million in 2022 and is forecasted to be growing at a CAGR of 7.2% to worth USD 212.47 million by 2027.

The market is predicted to grow substantially in the mentioned forecast period as well as years to follow. Immunohistochemistry is a medical procedure that includes staining on a fresh or stored cancer tissue that is removed out during biopsy. This technique assists in the detection of hormone receptors on the surface of cancer cells. Immunohistochemistry is majorly used for the diagnosis of cancers, especially tumor antibodies. It is an important application of monoclonal and polyclonal antibodies which helps doctors to know the tissue distribution of an antibody.

The increasing incidences of cancer, stabilization of the economy over the past years, growing expenditure on healthcare, developing infrastructure, and rising disposable income are driving the growth of the Immunotherapy market in Latin America. However, the high cost of the procedure and unstable reimbursement scenario are major factors that hamper the growth of this market.

This research report on Latin American Immunohistochemistry Market has been segmented and sub-segmented into the following categories:

By Product: 

• Antibodies
• Reagents
• Equipment
• Kits

By Application: 

• Diagnostics
• Drug Testing

By End User: 

• Hospitals
• Diagnostic Laboratories
• Research Institutes

By Country: 

• Brazil
• Mexico
• Argentina
• Chile
• Rest of Latin America

Companies that are playing a promising role in the Latin America Immunohistochemistry Market Profiled in the Report are F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc.